Virtu Financial’s Unicycive Therapeutics UNCY Stock Holding History

Virtu Financial’s Portfolio UNCY Stock Details UNCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$54K	Sell	11,610 -14,664	-56%	-$108K	﹤0.01%	1214
2026 Q1	$173K	Buy	+26,274	New	+$172K	0.01%	1059
2025 Q2	–	Sell	-3,887	Closed	-$22K	–	2047
2025 Q1	$22K	Buy	+3,887	New	+$23.7K	﹤0.01%	1096
2024 Q4	–	Sell	-7,398	Closed	-$30K	–	2080
2024 Q3	$30K	Buy	7,398 +6,289	+567%	+$25.3K	﹤0.01%	1085
2024 Q2	$6K	Sell	1,109 -1,499	-57%	-$14.7K	﹤0.01%	1176
2024 Q1	$36K	Buy	+2,608	New	+$31.6K	﹤0.01%	1077
2023 Q4	–	Sell	-1,099	Closed	-$9K	–	2027
2023 Q3	$9K	Buy	+1,099	New	+$10.3K	﹤0.01%	1119
2023 Q1	–	Sell	-1,546	Closed	-$8K	–	2123
2022 Q4	$8K	Buy	+1,546	New	+$10.5K	﹤0.01%	1414

Other funds holding UNCY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return

Virtu Financial's UNCY Position: Q2 2026 in Review

Virtu Financial reduced its Unicycive Therapeutics (UNCY) stake by 56% in Q2 2026, selling an estimated $108K and leaving 11,610 shares worth $54K. The position accounts for ﹤0.01% of the portfolio, ranked #1214.

Virtu Financial first reported a position in UNCY in Q4 2022 and has held it in 8 quarters since. The position peaked at $173K in Q1 2026. 80 funds tracked by Wall St. Rank hold UNCY as of Q2 2026.

Virtu Financial held 11,610 shares of Unicycive Therapeutics worth $54K as of Q2 2026.
Virtu Financial sold 14,664 Unicycive Therapeutics shares in Q2 2026, an estimated $108K.
Unicycive Therapeutics made up ﹤0.01% of Virtu Financial's portfolio in Q2 2026, its #1214 holding.
Virtu Financial first reported a position in Unicycive Therapeutics in Q4 2022 and has held it in 8 quarters since.
Virtu Financial's Unicycive Therapeutics position peaked at $173K in Q1 2026.
80 funds tracked by Wall St. Rank held Unicycive Therapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.